Skip to Content

Join the 'Canakinumab' group to help and get support from people like you.

Canakinumab News

FDA Approves Expanded Indications for Ilaris (canakinumab) for Three Rare Diseases

Posted 26 Sep 2016 by

September 23, 2016 – The U.S. Food and Drug Administration today approved three new indications for Ilaris (canakinumab). The new indications are for rare and serious auto-inflammatory diseases in adult and pediatric patients: Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS); Hyperimmunoglobulin D Syndrome (HIDS)/Mevalonate Kinase Deficiency (MKD); and Familial Mediterranean Fever (FMF). All three syndromes are hereditary diseases that are characterized by periodic attacks of fever and inflammation, as well as severe muscle pain. There are no previously approved therapies for TRAPS or HIDS/MKD. “For the first time, patients with TRAPS and HIDS/MKD, two painful and life altering diseases, have access to a treatment that may help improve their quality of life,” said Badrul Chowdhury, M.D., Ph.D, director of the Division of Pulmonary, Allergy and Rheumatology Products in ... Read more

Related support groups: Familial Mediterranean Fever, Ilaris, Hyperimmunoglobulin D Syndrome, Canakinumab, Tumor Necrosis Factor Receptor Associated Periodic Syndrome

Ilaris Approved by FDA to Treat Active Systemic Juvenile Idiopathic Arthritis

Posted 12 May 2013 by

Basel, May 10, 2013 - Novartis announced today that the US Food and Drug Administration (FDA) has approved Ilaris (canakinumab) for the treatment of active systemic juvenile idiopathic arthritis (SJIA) in patients aged 2 years and older. Ilaris is the first interleukin-1 beta (IL-1 beta) inhibitor approved for SJIA and the only treatment approved specifically for SJIA that is given as a once-monthly subcutaneous injection[1]. SJIA is a rare and disabling form of childhood arthritis characterized by spiking fever, rash and arthritis that can affect children as young as 2 years old and can continue into adulthood[2],[3]. This approval was based on two Phase III trials in SJIA patients, aged 2-19, showing significant improvement in the majority of Ilaris-treated patients[1]. Study 1 showed that 84% of patients treated with one subcutaneous dose of Ilaris achieved the primary endpoint of ... Read more

Related support groups: Juvenile Rheumatoid Arthritis, Juvenile Idiopathic Arthritis, Ilaris, Canakinumab

Drugs Hold Promise for Severe Juvenile Arthritis Patients

Posted 19 Dec 2012 by

WEDNESDAY, Dec. 19 – Children who suffer from a rare and painful form of arthritis that's accompanied by fever and rashes may soon have more treatment options. Two studies published in the Dec. 20 issue of the New England Journal of Medicine suggest that two drugs – canakinumab and tocilizumab – reduce symptoms, including severe joint pain experienced by children with systemic juvenile idiopathic arthritis (JIA). "Systemic juvenile idiopathic arthritis is a form of severe arthritis which until a few years ago was treated mainly with corticosteroids which have known side effects, especially growth impairment," said Dr. Nicolino Ruperto, a pediatric rheumatologist at G. Gaslini Children's Hospital in Genoa and co-author of the studies. The research looked at the safety and effectiveness of the interleukin-1 inhibitor canakinumab and the interleukin-6 inhibitor tocilizumab. The disease ... Read more

Related support groups: Rheumatoid Arthritis, Juvenile Rheumatoid Arthritis, Actemra, Juvenile Idiopathic Arthritis, Ilaris, Tocilizumab, Canakinumab

Ask a Question

Further Information

Related Condition Support Groups

Cryopyrin-Associated Periodic Syndromes, Familial Cold Autoinflammatory Syndrome, Juvenile Idiopathic Arthritis, Hyperimmunoglobulin D Syndrome, Familial Mediterranean Fever, Muckle Wells Syndrome, Tumor Necrosis Factor Receptor Associated Periodic Syndrome

Related Drug Support Groups


Canakinumab Patient Information at